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anti-intimal hyperplasia stent potency in all comer
patients undergoing percutaneous coronary intervention.
Results of the PRODIGY Trial, European Society of Cardi-
ology Scientific Congress, Paris (2011).
Summary: PRODIGY trial is an open-label, 4  2 randomized
trial designed to test the hypothesis that long course (24
months) of dual antiplatelet therapy (DAPT) is superior to
short course (6 months) following drug-eluting stent (DES)
implantation in all-comer percutaneous coronary interven-
tion (PCI) patients. It randomly allocated (balancing random-
ization) 2013 suitable patients on an intension to treat basis
to bare metal stents (BMS) (n ¼ 505), Endeavor Sprint
zotarolimus-eluting stent (Medtronic, Santa Rosa, CA)
(n ¼ 502), Taxus paclitaxel-eluting stent (Boston Scientific,
Natick, MA) (n ¼ 502), or Xience V everolimus-eluting stent
(Abbott Vascular, Santa Clara, CA) (n ¼ 502). At 30 days
following the index PCI, 1970 patients were eligible for
randomization to either 24monthsDAPT (n¼ 987) or 6months
DAPT (n ¼ 983) and both the groups were followed up for 24
months. The primary endpoint of all-cause mortality,
nonfatal myocardial infarction (MI), or stroke was almost
identical between the two groups [10.1% vs 10.0%, HR e 0.98
(0.74e1.29), p ¼ 0.91]. The individual efficacy secondary
endpoints of death from any cause [6.6% vs 6.6%, HR e 1.00
(0.72e1.40), p ¼ 0.98], and death from any cause or MI [8.9% vs
9.6%, HR e 1.07 (0.80e1.43), p ¼ 0.62] were also not statistically
significant between the groups. However, the safety endpoints
of type 2, 3, or 5 Bleeding Academic Research Consortium
(BARC) bleeding [7.4% vs 3.5%, HR e 0.46 (0.1e0.69),
p ¼ 0.00018], TIMI major bleeding (1.6% vs 0.6%, p ¼ 0.041) and
red blood cell transfusion (2.6% vs 1.3%, p ¼ 0.041) were
significantly worse with the long course DAPT cohort. In the
landmark analysis between 6 and 24 months, again the
primary endpoints were not statistically different [7.2% vs
6.4%, HR e 0.53 (0.64e1.25), p ¼ 0.53]. They were also not
different among the various subgroups. (All the results are
read as 24 months DAPT vs 6 months DAPT.)Clinical perspective
Multitudes of reports have shown continued proneness of DES
to late and very late stent thrombosis (ST). The current
recommendation of 1 year of DAPT following DES implanta-
tion is based on limited data and expert opinion (level of
evidence C). The REAL-LATE/ZEST-LATE trial (Park SJ, et al. N
Engl J Med 2010) that comparedmore than 1 year vs less than 1
year of DAPT did not show any advantage of long term DAPT.
Similarly, the EXCELLENT trial (Kim HS, TCT 2010) which
evaluated more than 6 months vs less than 6 months of DAPT
was also did not support the long-term DAPT. Moreover, both
the trials have suggested high bleeding events in the long-
term DAPT cohort. However, both the trials were criticized
for flaws in their methodology. In this background, the
PRODIGY trial was presented in the ESC 2011 conference. Thisis a well designed, industry independent, all comer trial (74%
with acute coronary syndrome and 24% with stable angina)
with excellent drug compliance and follow up. Further, it also
included BMSs, a 1st generation DES and two 2nd generation
DESs in a 1:1:1:1 fashion. The outcomes were similar to the
other two trials with no difference in the ischemic endpoints
and significantly increased bleeding risk. The results of these
three trials question the value of long-term DAPT following
DES implantation in the wake of increased bleeding risk.
However, with the relatively small sample size in all the three
trials, it may not possible to make a definitive conclusion
regarding the duration of DAPT. We still have to await the
results of large population studies like Dual Antiplatelet
Therapy (DAPT) Study.
2. G.W. Stone, P.S. Teirstein, I.T. Meredith, et al., (PLATINUM
Trial Investigators). A prospective, randomized evaluation
of a novel everolimus-eluting coronary stent. The PLAT-
INUM (A prospective, randomized, multicenter trial to
assess an everolimus-eluting coronary stent system
[PROMUS element] for the treatment of up to two de novo
coronary artery lesions) Trial (PLATINUM Workhorse
(WH) Trial). J. Am. Coll. Cardiol. 57 (2011) 1700e1708,
http://dx.doi.org/10.1016/j.jacc.2011.02.016.
Summary: PLATINIUMWH is a non-inferiority trial comparing
the newer biocompatible durable polymer platinum chro-
mium everolimus-eluting stent (PtCr-EES) with a predicate
cobalt chromium everolimus-eluting stent (CoCr-EES). This
trial enrolled 1530 patients (1:1 fashion) with up to two de
novo lesions at 132 clinical sites worldwide. The primary
end-point was the 12-month target lesion failure (TVF),
defined as any ischemia-driven target vessel revasculariza-
tion (TVR), myocardial infarction (MI) (Q-wave and non-
Q-wave) related to the target vessel, or cardiac death related
to the target vessel. The study met its non-inferiority primary
end-point at 1 year [TLF e 2.9% (CoCr-EES) vs 3.4% (PtCr-EES),
Pnoninferiority¼ 0.001]. The 1-year TLR rate was 1.9% for both the
groups and similarly ARC definite or probable ST occurred in 3
patients (0.4%) in each group. However, the CoCr-EES arm
required more bail-out stenting compared to PtCr-EES arm
(9.9% vs 5.9%, p ¼ 0.004), partly resulting from a higher rate of
inadequate lesion coverage in the CoCr-EES group (3.4% vs
1.4%, p ¼ 0.01).
Two-year outcomes of the PLATINIUMWHwere presented
at the American College of Cardiology Annual Scientific
Sessions in Chicago. At 2-years, TLF was 4.4% for the PtCr-EES
cohort compared to 5.8% for the CoCr-EES cohort (p ¼ 0.32). In
a landmark analysis of event rates between year 1 and 2, the
PtCr-EES demonstrated statistically significant differences in
TLF (1.2% vs 3.0%, p ¼ 0.04, 56% relative reduction), and TLR
(0.7% vs 2.2%, p¼ 0.02, 67% relative reduction) compared to the
CoCr-EES, showing superior efficacy of the PtCr-EES from 12
months to 2 years.Clinical perspective
Second generation biocompatible polymer limus stents
have shown excellent safety and efficacy outcomes in real
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intervention to more complex lesion subsets. The PROMUS
Element (Boston Scientific, Natick, MA) is a novel stent
platform made up of newer platinum chromium alloy
(PtCr), the material properties of which provide increased
radial strength and fracture resistance and enhanced radio-
opacity. These properties allow thinner struts (81 m)
resulting in lesser vascular injury and improved visibility
enhancing optimal lesion coverage and less geographic
miss compared to older stent platforms. It uses the same
durable polymer and anti-proliferative drug as the predi-
cate CoCr-EES. The PLATINUM clinical programme is eval-
uating the performance of this newer stent platform in six
multicenter clinical studies involving more than 1900
patients. The PLATINUM WH trial compared the PtCr-EES
platform with the predicate second generation CoCr-EES.
At 1 year the PtCr-EES met the noninferiority endpoint and
continued to show excellent efficacy and safety outcomes
at 2 years and in the landmark analysis, the outcomes after
1 year were better with the PtCr-EES platform. With its
improved visibility and deliverability, the PtCr-EES cohort
had less incidence of geographic-miss and the resultant
fewer of bail-out stenting. The PLATINIUM Small Vessel
Subtrial (n ¼ 94) also met the primary outcomes at 1 year
and at 2 years TLF rate for 2.25 mm PROMUS Element stent
was 4.7% with a TLR rate of 2.5% (BSC, Press Release, May
18, 2012). Results are expected from the ongoing trials (Long
Lesion Subtrial, Pharmacokinetics Subtrial, and Quantita-
tive Coronary Angiography/IVUS Trial) are expected in the
near future. The recent publications of longitudinal defor-
mation with the PtCr stent platform have raised concern
among the interventional cardiologist. However, the QCA
data from the PLATINUM WH and PERSEUS WH trials pre-
sented in the recent ACC scientific sessions did not show
increased incidence of longitudinal deformation when
compared with TAXUS and PROMUS/Xience V stent plat-
forms. With more evidence, the PROMUS-Element stent
platform might become an excellent addition to the exist-
ing armamentarium of DES that broadens the choice DES to
the clinicians.
3. P. Ge´ne´reux, T. Palmerini, A. Caixeta, et al. Quantification
and impact of untreated coronary artery disease after
percutaneous coronary intervention: the Residual SYNTAX
(Synergy Between PCI With Taxus and Cardiac Surgery)
Score. J. Am. Coll. Cardiol. (2012 Mar 31) [Epub ahead of
print].
Objectives: The purpose of this study was to quantify the
extent and complexity of residual coronary stenoses following
percutaneous coronary intervention (PCI) and to evaluate its
impact on adverse ischemic outcomes.
Background: Incomplete revascularization (IR) after PCI is
common, and most studies have suggested that IR is associ-
ated with a worse prognosis compared with complete revas-
cularization (CR). However, formal quantification of the extent
and complexity of residual atherosclerosis after PCI has not
been performed.
Methods: The baseline Synergy Between PCI With Taxus
and Cardiac Surgery (SYNTAX) score (bSS) from 2686angiograms from patients withmoderate- and high-risk acute
coronary syndrome (ACS) undergoing PCI enrolled in the
prospective ACUITY (Acute Catheterization and Urgent
Intervention Triage Strategy) trial was determined. The SS
after PCI was also assessed, generating the “residual” SS (rSS).
Patients with rSS >0 were defined as having IR and were
stratified by rSS tertiles, and their outcomeswere compared to
the CR group.
Results: The bSS was 12.8  6.7, and after PCI the rSS was
5.6  2.2. Following PCI, 1084 patients (40.4%) had rSS ¼ 0 (CR),
523 (19.5%) had rSS >0 but 2578 (21.5%) had rSS >2 but 8,
and 501 patients (18.7%) had rSS >8. Age, insulin-treated dia-
betes, hypertension, smoking, elevated biomarkers or ST-
segment deviation, and lower ejection fraction were more
frequent in patients with IR compared with CR. The 30-day
and 1-year rates of ischemic events were significantly higher
in the IR group compared with the CR group, especially those
with high rSS. By multivariable analysis, rSS was a strong
independent predictor of all ischemic outcomes at 1 year,
including all-cause mortality (hazard ratio: 1.05, 95% confi-
dence interval: 1.02e1.09, p ¼ 0.006).
Conclusions: The rSS is useful to quantify and risk-stratify
the degree and complexity of residual stenosis after PCI.
Specifically, rSS >8.0 after PCI in patients with moderate- and
high-risk ACS is associated with a poor 30-day and 1-year
prognosis (Comparison of Angiomax Versus Heparin in
Acute Coronary Syndromes; NCT00093158).Clinical perspective
SYNTAX Score is an excellent tool to quantify the anatomic
extent and complexity of coronary atherosclerosis in
patients undergoing revascularization by percutaneous
coronary intervention (PCI) and it has also been shown
predicts outcomes in this population. The current study
assessed the completeness of revascularization by calcu-
lating rSS in ACUITY-PCI population and showed that high
rSS was associated with poor outcomes at 30 days and 1-
year following revascularization in moderate to high risk
ACS population. Compared with patients with CR, patients
with IR had either higher baseline clinical risk profile or
more complex coronary disease (longer lesions, calcified
lesions, chronic total occlusions and triple vessel disease).
CR was associated with better outcomes in patients with
higher bSS compared to those with lower bSS which might
have resulted from higher baseline ischemic burden. Even
though it is desirable to achieve complete revascularization
by either PCI or CABG particularly in patients with higher
baseline SS, it is not always possible in real life scenario. For
instance, in the current study CR was achieved only in 40.4%
of the patients and in the SYNTAX trial, even in the hands of
experts the complete revascularization rates were only
62.3% in the CABG group and 56.7% in the PCI group, influ-
enced largely by patient or lesion complexity or both.
Moreover, we now know that angiography is not an optimal
tool to assess the lesion significance and need additional
functional assessment particularly in intermediate lesions.
Further, viability status in the territory supplied by the
stenotic vessel also plays a major role in improving patient
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incomplete revascularization is not consistent among the
trials. In spite of the above limitations, rSS may help us to
identify subset of patients at risk of adverse events
following PCI who might benefit from additional revascu-
larization if possible or by aggressive medical treatment and
close follow-up.
4. G.G. Stefanini, B. Kalesan, P.W. Serruys, et al. Long-term
clinical outcomes of biodegradable polymer biolimus-
eluting stents versus durable polymer sirolimus-eluting
stents in patients with coronary artery disease
(LEADERS): 4 year follow-up of a randomised non-
inferiority trial. Lancet 378 (2011) 1940e1948.
Background: The effectiveness of durable polymer drug-
eluting stents comes at the expense of delayed arterial heal-
ing and subsequent late adverse events such as stent throm-
bosis (ST). We report the 4-year follow-up of an assessment of
biodegradable polymer-based drug-eluting stents, which aim
to improve safety by avoiding the persistent inflammatory
stimulus of durable polymers.
Methods: We did a multicentre, assessor-masked, non-
inferiority trial. Between Nov 27, 2006, and May 18, 2007,
patients aged 18 years or older with coronary artery disease
were randomly allocated with a computer-generated
sequence to receive either biodegradable polymer biolimus-
eluting stents (BES) or durable polymer sirolimus-eluting
stents (SES; 1:1 ratio). The primary endpoint was
a composite of cardiac death, myocardial infarction, or clini-
cally indicated target vessel revascularisation (TVR); patients
were followed-up for 4 years. Analysis was by intention to
treat. This trial is registered with ClinicalTrials.gov, number
NCT00389220.
Findings: 1707 patients with 2472 lesions were randomly
allocated to receive either biodegradable polymer BES (857
patients, 1257 lesions) or durable polymer SES (850
patients, 1215 lesions). At 4 years, biodegradable polymer
BES were non-inferior to durable polymer SES for the
primary endpoint: 160 (18.7%) patients versus 192 (22.6%)
patients (rate ratios [RR] 0.81, 95% CI 0.66e1.00, p for non-
inferiority <0.0001, p for superiority ¼ 0.050). The RR of
definite ST was 0.62 (0.35e1.08, p ¼ 0.09), which was largely
attributable to a lower risk of very late definite ST between
years 1 and 4 in the BES group than in the SES group (RR
0.20, 95% CI 0.06e0.67, p ¼ 0.004). Conversely, the RR of
definite ST during the first year was 0.99 (0.51e1.95;
p ¼ 0.98) and the test for interaction between RR of definite
ST and time was positive (Pinteraction ¼ 0.017). We recorded
an interaction with time for events associated with ST but
not for other events. For primary endpoint events associ-
ated with ST, the RR was 0.86 (0.41e1.80) during the first
year and 0.17 (0.04e0.78) during subsequent years
(Pinteraction ¼ 0.049).
Interpretation: Biodegradable polymer BES are non-inferior
to durable polymer SES and, by reducing the risk of cardiac
events associated with very late ST, might improve long-term
clinical outcomes for up to 4 years compared with durable
polymer SES.Clinical perspective
Durable polymers in the first generation drug-eluting stents
(DES) have been shown to be responsible for persistent
vascular inflammatory response and delayed arterial healing
with resultant late adverse events. The biodegradable
biolimus-eluting stent (BES) is designed in such a way that it
offers an attractive combination of controlled drug elusion in
parallel with biodegradation of the abluminal polymer into
inert monomers within 6e9 months and only a bare-metal
stent (BMS) remains thereafter. In the all-comer LEADERS
trial, the BES stent met the noninferiority composite
endpoint of death, myocardial infarction and target vessel
revascularization at 9 months (BES: 9% vs SES: 11%, p ¼ 0.39).
The study population was followed up further for 3 years for
the durability of the safety and efficacy outcomes. At the end
of 4 years, BES not only met the primary outcomes and was
also associated with lower incidence of very late definite
stent thrombosis (0.12%/year vs 0.6%/year). In the subgroup
analysis, BES showed a pronounced advantage in patients
with ST-elevation myocardial infarction. The notable
features of this study are: (1) the safety outcomes were
evident only after the first year that is after complete
degradation of the polymer e the proof of concept for the
biodegradable polymer, (2) long-term durability of the anti-
restenotic efficacy (3) higher incidence of definite ST in the
presence of long-term dual antiplatelet therapy in the SES
cohort e underlining the continued proneness of this stent
platform to very late thrombosis (4) even though the TLR, MI,
and primary composite endpoint were numerically better,
the study was not powered to show the superiority of BES
over SES. This was elegantly shown in the pooled analysis of
the individual patient data from three studies comparing
biodegradable polymer stents and durable polymer SES
(Stefanini GG, et al, Eur Heart J 2012). (5) Superior outcomes in
patients with STEMI, even though this study was not pow-
ered for this outcome. However, the COMFORTABLE AMI trial
presented in EuroPCR 2012 has shown excellent safety
outcomes for BES when compared to BMS with significantly
lower incidence of target vessel reinfarction, TVR, and ST at 1
year. In conclusion, long-term results from the LEADERS and
similar trials provide encouraging evidence for the clinical
use of biodegradable polymer stent platforms.
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Effectiveness of percutaneous coronary intervention (PCI) and
coronary artery bypass grafting (CABG) for the treatment of
patients with stable multi-vessel coronary artery disease is
